Krystal Biotech (KRYS) Gains from Investment Securities (2016 - 2026)

Krystal Biotech has disclosed Gains from Investment Securities across 11 years of filings, most recently posting $529000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $529000.0, down 70.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $513000.0 (down 71.53% YoY), and the FY2025 annual result was $1.8 million, changed N/A from the prior year.
• Gains from Investment Securities came in at $529000.0 for Q1 2026 at Krystal Biotech, up from -$3.8 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $12.1 million in Q2 2025 to a low of -$8.3 million in Q3 2025.
• The 5-year median for Gains from Investment Securities is $1.1 million (2022), against an average of $241937.5.
• Across the five-year window, Gains from Investment Securities jumped 21471.43% in 2023 and plunged 462.68% in 2025, its largest moves.
• Krystal Biotech's Gains from Investment Securities stood at $1.6 million in 2022, then slumped by 346.26% to -$3.9 million in 2023, then sank by 32.53% to -$5.1 million in 2024, then climbed by 26.93% to -$3.8 million in 2025, then surged by 114.06% to $529000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $529000.0 (Q1 2026), -$3.8 million (Q4 2025), and -$8.3 million (Q3 2025), per Business Quant data.